Cargando…
Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
Purpose. Fluorescein angiographic studies revealed prolonged arteriovenous passage (AVP) times and increased fluorescein filling defects in normal tension glaucoma (NTG) compared to healthy controls. The purpose of this study was to correlate baseline AVP and fluorescein filling defects with visual...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824313/ https://www.ncbi.nlm.nih.gov/pubmed/24282387 http://dx.doi.org/10.1155/2013/726912 |
_version_ | 1782290691210084352 |
---|---|
author | Koch, Eva Charlotte Arend, Kay Oliver Bienert, Marion Remky, Andreas Plange, Niklas |
author_facet | Koch, Eva Charlotte Arend, Kay Oliver Bienert, Marion Remky, Andreas Plange, Niklas |
author_sort | Koch, Eva Charlotte |
collection | PubMed |
description | Purpose. Fluorescein angiographic studies revealed prolonged arteriovenous passage (AVP) times and increased fluorescein filling defects in normal tension glaucoma (NTG) compared to healthy controls. The purpose of this study was to correlate baseline AVP and fluorescein filling defects with visual field progression in patients with NTG. Patients and Methods. Patients with a follow-up period of at least 3 years and at least 4 visual field examinations were included in this retrospective study. Fluorescein angiography was performed at baseline using a confocal scanning laser ophthalmoscope (SLO, Rodenstock Instr.); fluorescein filling defects and AVP were measured by digital image analysis and dye dilution curves (25 Hz). Visual field progression was evaluated using regression analysis of the MD (Humphrey-Zeiss, SITA-24-2, MD progression per year (dB/year)). 72 patients with NTG were included, 44 patients in study 1 (fluorescein filling defects) and 28 patients in study 2 (AVP). Results. In study 1 (mean follow-up 6.6 ± 1.9 years, 10 ± 5 visual field tests), MD progression per year (−0.51 ± 0.59 dB/year) was significantly correlated to the age (P = 0.04, r = -0.29) but not to fluorescein filling defects, IOP, or MD at baseline. In study 2 (mean follow-up 6.6 ± 2.2 years, 10 ± 5 visual field tests), MD progression per year (−0.45 ± 0.51 dB/year) was significantly correlated to AVP (P = 0.03, r = 0.39) but not to age, IOP, or MD at baseline. Conclusion. Longer AVP times at baseline are correlated to visual field progression in NTG. Impaired retinal blood flow seems to be an important factor for glaucoma progression. |
format | Online Article Text |
id | pubmed-3824313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-38243132013-11-26 Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma Koch, Eva Charlotte Arend, Kay Oliver Bienert, Marion Remky, Andreas Plange, Niklas ScientificWorldJournal Clinical Study Purpose. Fluorescein angiographic studies revealed prolonged arteriovenous passage (AVP) times and increased fluorescein filling defects in normal tension glaucoma (NTG) compared to healthy controls. The purpose of this study was to correlate baseline AVP and fluorescein filling defects with visual field progression in patients with NTG. Patients and Methods. Patients with a follow-up period of at least 3 years and at least 4 visual field examinations were included in this retrospective study. Fluorescein angiography was performed at baseline using a confocal scanning laser ophthalmoscope (SLO, Rodenstock Instr.); fluorescein filling defects and AVP were measured by digital image analysis and dye dilution curves (25 Hz). Visual field progression was evaluated using regression analysis of the MD (Humphrey-Zeiss, SITA-24-2, MD progression per year (dB/year)). 72 patients with NTG were included, 44 patients in study 1 (fluorescein filling defects) and 28 patients in study 2 (AVP). Results. In study 1 (mean follow-up 6.6 ± 1.9 years, 10 ± 5 visual field tests), MD progression per year (−0.51 ± 0.59 dB/year) was significantly correlated to the age (P = 0.04, r = -0.29) but not to fluorescein filling defects, IOP, or MD at baseline. In study 2 (mean follow-up 6.6 ± 2.2 years, 10 ± 5 visual field tests), MD progression per year (−0.45 ± 0.51 dB/year) was significantly correlated to AVP (P = 0.03, r = 0.39) but not to age, IOP, or MD at baseline. Conclusion. Longer AVP times at baseline are correlated to visual field progression in NTG. Impaired retinal blood flow seems to be an important factor for glaucoma progression. Hindawi Publishing Corporation 2013-10-24 /pmc/articles/PMC3824313/ /pubmed/24282387 http://dx.doi.org/10.1155/2013/726912 Text en Copyright © 2013 Eva Charlotte Koch et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Koch, Eva Charlotte Arend, Kay Oliver Bienert, Marion Remky, Andreas Plange, Niklas Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma |
title | Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma |
title_full | Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma |
title_fullStr | Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma |
title_full_unstemmed | Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma |
title_short | Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma |
title_sort | arteriovenous passage times and visual field progression in normal tension glaucoma |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824313/ https://www.ncbi.nlm.nih.gov/pubmed/24282387 http://dx.doi.org/10.1155/2013/726912 |
work_keys_str_mv | AT kochevacharlotte arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma AT arendkayoliver arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma AT bienertmarion arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma AT remkyandreas arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma AT plangeniklas arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma |